Institut Curie;ABIVAX;UNIVERSITE DE MONTPELLIER;Centre National de la Recherche Scientifique
发明人:
申请号：
EP18305910.4
公开号：
EP3594206A1
申请日:
2018.07.09
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to a compound of formula (I)wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group or a -O-P(=O)-(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection, and in particular a RNA virus infection from group IV or V of the Baltimore classification.The present invention further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.
